The Pulse
Danaher Targets 8× Faster Antibody-Reagent Discovery With AI Lab
Danaher says its planned AI-powered lab at Abcam is designed to discover affinity reagents up to eight times faster and generate up to ten times more reagents annually as it scales. The company expects the facility to operate at scale in ea
AI.info Team · Written with AI ·
Danaher sets an early-2027 target for the lab
Danaher announced on October 7, 2026, that it plans to launch its first AI-powered autonomous lab, a facility intended to develop custom antibodies and other molecular tools. The company expects the lab to operate at scale in early 2027. It will be based at Abcam, a Danaher company.
The planned lab will bring artificial intelligence, robotics and technologies from several Danaher operating companies into one connected workflow. Danaher says it is designed to discover affinity reagents—molecules that bind to specific biological targets—up to eight times faster, and to increase annual reagent generation by as much as tenfold, from tens to hundreds as the lab scales. These are projected capabilities: the announcement reports no demonstrated gains or results from an operating facility.
A design-build-test cycle links software to experiments
The proposed workflow uses AI to help create affinity reagents, including antibodies, then builds and tests each candidate. Results are fed back into the model to inform the next design, forming what the company calls a continuous design-make-test-learn loop. Danaher says each design will be verified and tested, with scientists continuing to make key decisions.
The workflow combines capabilities from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices. Automata collaborated on device orchestration and robotic automation. Danaher’s announcement notes that Automata received an investment from Danaher in January 2026.
The company says its approach is expected over time to complement traditional immunization-based methods used to discover antibodies and other research tools. It also says models may help researchers prioritize promising designs before they are made, while robotics can support more consistent experimentation.
Danaher describes a wider connected-science program
Danaher presents the antibody lab as an early proof point in a broader program to develop smart instruments that are easier to integrate and control programmatically, produce AI-ready data, and include agentic systems. The company says those instruments could be connected into workflows and autonomous labs that carry out design-make-test-learn cycles. It describes the wider effort as intended to simplify instrument operation, improve data quality and generate deeper insights.
JC Gutierrez-Ramos, Danaher’s senior vice president and chief science officer, described the role of repeated experimental cycles:
“Every result sharpens the next design, so the faster each loop runs, the faster discovery compounds.”
He said scientists would continue to make the key decisions, leaving them to focus on scientific challenges where human insight matters. Danaher says the lab is intended to move researchers from an idea to a validated reagent faster, while maintaining testing and verification.
Performance remains a stated target
The announcement does not provide a budget, name outside customers, or report performance measurements from the facility. Its claims about speed, reagent output and the broader effects of the platform are forward-looking; the company cautions that actual results and developments may differ from those expectations. Danaher’s stated milestone is operation at scale in early 2027. Its stated targets are up to eight times faster progress from idea to validated reagent and up to tenfold more annual reagent generation as the lab scales.